410 • 500 22nd Street South
1530 3rd Avenue South
Birmingham, AL 35294-0104
NON PROFIT
U.S. Postage
PAID
Permit #1256
Birmingham, AL
uabmedicine.org/learnmd
FOR FREE CME CREDIT
UAB MEDICINE
PULMONARY SERVICES
SPRING 2020
INSIDE THIS ISSUE:
• MACHINES HELP SCIENTISTS SPOT NEW
PATTERNS IN COPD
• UAB PULMONARY FACULTY DEVELOP
COVID-19 CARE GUIDELINES, EARN
RESEARCH GRANTS
• RESEARCH POINTS TO POSSIBLE TARGET
FOR TREATING IPF
• END-OF-LIFE SPENDING AND HEALTH
CARE UTILIZATION AMONG OLDER ADULTS
WITH COPD
• UAB HOSTS SECOND ANNUAL ‘LOVE YOUR
LUNGS’ EXPO
Contact UAB Medicine’s 24-hour consultation and referral service at 800.UAB.MIST or mist@uabmc.edu.
CLINICAL TRIALS
Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD – PI:
Surya P. Bhatt, MD
This is a prospective study to determine the relationships between pauciinflammatory
exacerbations and diastolic dysfunction, and their implications in
hospitalized patients with acute exacerbations of COPD. To assess changes within
subjects from the stable to acute phase, a number of comparisons will be made in
subjects enrolled during acute exacerbation, with similar measurements made in
the stable phase after recovery from exacerbation after at least 35 days from index
hospitalization or prior exacerbation.
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X
Premature Termination Codon Mutations – PI: Steven M. Rowe, MD
Based on previous clinical findings, the investigator hypothesize that ivacaftor
will have synergistic effects with drugs that facilitate truncated but partially active
W1282X CFTR protein processing (tezacaftor) in patients with W1282X CFTR. In the
current study, the investigators propose to directly test the efficacy of tezacaftor/
ivacaftor (TEZ/IVA) for W1282X CFTR therapy in the clinic in comparison to ivacaftor
alone.
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis - PI: Steven R.
Duncan, MD
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory
patients with idiopathic pulmonary fibrosis. The investigators hypothesize that
the drug will decrease pulmonary injury due to reactive oxygen species (ROS)
generated by NOX enzymes, which are believed to play an important role in the
development of IPF.
VX-770 for the Treatment of Chronic Bronchitis - PI: George Solomon, MD
This study will test how well a new drug affects bronchiectasis or chronic bronchitis.
The new drug, ivacaftor (Kalydeco), recently was approved by the U.S. Food and
Drug Administration for patients with cystic fibrosis. It has not been approved for
use in patients with bronchiectasis or chronic bronchitis.
For more information or to contact a clinical trial team, visit
xpertdox.com/uab-trial.
SELECTED PUBLICATIONS
Iyer AS, Goodrich CA, Dransfield MT, Alam SS, Brown CJ, Landefeld CS, Bakitas MA,
Brown JR. End-of-Life Spending and Healthcare Utilization Among Older Adults with
Chronic Obstructive Pulmonary Disease. Am J Med. 2019 Dec 26;S0002-9343(19)31105-2.
doi: 10.1016/j.amjmed.2019.11.024. [Epub ahead of print]. PMID: 31883772
Raju SV. What Doesn’t Kill You Makes You Weaker. Am J Physiol Lung Cell Mol Physiol.
2019;317(6):L891–L892. doi:10.1152/ajplung.00432.2019
Wells JM, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O’Neal
W, Hoffman EA, Gaggar A, Barjaktarevic I, Curtis JL, Labaki WW, Han MLK, Freeman
CM, Putcha N, Schlange T, Blalock JE; SPIROMICS Investigators,. The matrikine acetylproline-glycine-proline
and clinical features of COPD: findings from SPIROMICS. Respir
Res. 2019 Nov 12;20(1):254. doi: 10.1186/s12931-019-1230-8. PMID: 31718676; PMCID:
PMC6852714
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW,
Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N,
Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl
J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
PMID: 31697873
Hwangpo T, Wang Z, Ghably J, Bhatt SP, Cui X, Schroeder HW Jr. Use of FEF25-75% to
Guide IgG Dosing to Protect Pulmonary Function in CVID [published online ahead of print,
2020 Jan 3]. J Clin Immunol. 2020;10.1007/s10875-019-00730-4. doi:10.1007/s10875-019-
00730-4
Larson-Casey JL, He C, Carter AB. Mitochondrial Quality Control in Pulmonary Fibrosis
[published online ahead of print, 2020 Jan 8]. Redox Biol. 2020;101426. doi:10.1016/j.
redox.2020.101426
Hough KP, Deshane JS. Cutting-Edge Approaches for Rapid Characterization of Airway
Exosomes [published online ahead of print, 2020 Jan 14]. Methods. 2020;S1046-
2023(19)30275-0. doi:10.1016/j.ymeth.2020.01.003
Kato K, Logsdon NJ, Shin YJ, Palumbo S, Knox A, Irish JD, Rounseville SP, Rummel
SR, Mohamed M, Ahmad K, Trinh JM, Kurundkar D, Knox KS, Thannickal VJ, Hecker
L. Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in
Aging. Am J Respir Cell Mol Biol. 2020 Jan 21;10.1165/rcmb.2019-0092OC. doi: 10.1165/
rcmb.2019-0092OC. [Epub ahead of print]. PMID: 31962055